Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of intravenous treatment for hypoglycaemia (yes/no) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).
1 finding from 1 review
Separation from mother for treatment of hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in separation from mother for treatment of hypoglycaemia (infant nursed… compared with placebo (low certainty).
1 finding from 1 review
Breastfeeding (exclusive after discharge) ‐ not reported (WHO 2008 definition (yes/no)) · newborn infants at risk of neonatal hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD at 28 days · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as an oxygen requirement at 28 days№ of participants:… compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.94, 1.26]
Studies not reported
Very low
Bronchopulmonary dysplasia · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as oxygen at 36 weeks' postmenstrual age№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.96 [0.72, 1.29]
Studies not reported
Very low
Neonatal mortality · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes neonatal mortality (i.e. within 28 days)№ of participants: 335(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.98 [0.57, 1.68]
Studies not reported
Very low
Mortality before hospital discharge · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes mortality prior to discharge№ of participants: 78(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 1.2 [0.53, 2.71]
Studies not reported
Very low
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retinopathy of prematurity · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes retinopathy of prematurity№ of participants: 277(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.95 [0.78, 1.15]
Studies not reported
Very low
Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes severe retinopathy of prematurity (stage II or greater)№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.97 [0.57, 1.65]
Studies not reported
Very low
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death at hospital discharge · preterm infants at risk for apnea
It is very uncertain whether methylxanthine changes death at hospital discharge compared with placebo or control (very low certainty).
1 finding from 1 review
Major neurodevelopmental disability at childhood · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
a) Cerebral palsy or gross motor disability · preterm infants at risk for apnea
Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
Developmental delay at ≥ 18 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in b) Developmental delay compared with placebo or control (moderate certainty).
1 finding from 1 review